source
- Henlius Biotech signs $440 million deal with Amberstone to develop T-cell engagersHenlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with California‑based Amberstone Biosciences valued at up to $440 million. The partnership will focus on creating anti…
- Roche signs $2 billion deal with Atavistik to discover allosteric cardiovascular-renal-metabolic drugsRoche announced a partnership with Cambridge-based biotech Atavistik Bio to develop allosteric small-molecule therapies for cardiovascular, renal and metabolic diseases. The agreement includes an u…